VN-0200 / Daiichi Sankyo - LARVOL DELTA

Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study. (PubMed, Hum Vaccin Immunother) - "There were no serious vaccine-related treatment-emergent adverse events (TEAEs) or vaccine-related TEAEs leading to death. All antigen/adjuvant dose combinations of VN-0200 were well tolerated and elicited an increase in anti-RSV/A and anti-RSV/B neutralization activity from baseline to Day 29 and Day 57."

Clinical • Journal • P2 data • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

A Dose Finding Study of VN-0200 (clinicaltrials.gov) - P2 | N=342 | Completed | Sponsor: Daiichi Sankyo | Active, not recruiting ➔ Completed | Trial primary completion date: Dec 2023 ➔ Apr 2023

Trial completion • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Dose Finding Study of VN-0200 (clinicaltrials.gov) - P2 | N=340 | Active, not recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

A Dose Finding Study of VN-0200 (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

A Dose Finding Study of VN-0200 (clinicaltrials.gov) - P2 | N=340 | Not yet recruiting | Sponsor: Daiichi Sankyo Co., Ltd.

New P2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Daiichi Sankyo Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG